Risk factors for calculated NIH global severity
| . | Moderate/severe versus mild (625 vs 100 assessments) . | Severe versus mild/moderate (195 vs 530 assessments) . | ||
|---|---|---|---|---|
| OR (95% CI) . | P . | OR (95% CI) . | P . | |
| Age at transplantation, y | ||||
| Adult < 50 | 1.0 | 1.0 | ||
| Adult ≥ 50 | 0.96 (0.5-1.9) | .91 | 0.96 (0.6-1.6) | .86 |
| Sex | ||||
| Male | 1.0 | 1.0 | ||
| Female | 0.81 (0.4-1.7) | .58 | 0.95 (0.6-1.6) | .85 |
| Donor/patient sex | ||||
| Other | 1.0 | 1.0 | ||
| Female to male | 0.46 (0.2-1.0) | .04 | 0.91 (0.5-1.6) | .75 |
| Donor | ||||
| HLA-matched related | 1.0 | 1.0 | ||
| HLA-matched URD | 0.74 (0.3-1.6) | .43 | 1.10 (0.6-1.9) | .73 |
| HLA-mismatched | 0.66 (0.3-1.6) | .37 | 1.41 (0.6-3.1) | .40 |
| Conditioning | ||||
| Myeloablative | 1.0 | 1.0 | ||
| RIC/NMA | 1.05 (0.5-2.2) | .89 | 1.36 (0.7-2.6) | .36 |
| Stem cell source | ||||
| Peripheral blood | 1.0 | 1.0 | ||
| BM | 0.68 (0.2-2.1) | .55 | 1.38 (0.5-3.8) | .56 |
| Cord blood | 2.70 (0.7-11) | .17 | 0.84 (0.2-4.2) | .83 |
| Patient CMV | ||||
| − | 1.0 | 1.0 | ||
| + | 0.94 (0.5-1.7) | .84 | 0.92 (0.5-1.6) | .76 |
| Donor CMV | ||||
| − | 1.0 | 1.0 | ||
| + | 1.04 (0.6-1.9) | .90 | 1.01 (0.6-1.7) | .98 |
| Diagnosis | ||||
| ALL/AML | 1.0 | 1.0 | ||
| CLL/CML | 0.40 (0.1-1.1) | .13 | 0.78 (0.3-1.9) | .56 |
| MDS | 0.89 (0.4-2.2) | .80 | 0.84 (0.4-1.8) | .65 |
| HD/NHL | 0.36 (0.2-0.8) | .03 | 1.16 (0.5-2.7) | .72 |
| Other | 0.45 (0.2-1.3) | .18 | 0.40 (0.2-1.0) | .05 |
| Disease stage | ||||
| Early | 1.0 | 1.0 | ||
| Intermediate | 1.22 (0.6-2.6) | .60 | 1.12 (0.6-2.1) | .72 |
| Advanced | 1.47 (0.6-3.5) | .38 | 1.23 (0.6-2.4) | .55 |
| KPS at chronic GVHD onset | ||||
| 80+ | 1.0 | 1.0 | ||
| ≤ 70 | 2.71 (1.4-5.1) | .001 | 2.19 (1.4-3.4) | .0007 |
| Missing | 0.95 (0.5-1.9) | .88 | 1.38 (0.8-2.3) | .24 |
| Prior acute GVHD | ||||
| No | 1.0 | 1.0 | ||
| Yes | 1.55 (0.9-2.8) | .15 | 0.89 (0.5-1.5) | .67 |
| Time to onset, mo | ||||
| < 6 | 1.0 | 1.0 | ||
| 6-12 | 0.71 (0.4-1.2) | .23 | 0.81 (0.5-1.4) | .42 |
| ≥ 12 | 1.95 (0.6-6.0) | .20 | 1.08 (0.5-2.2) | .83 |
| Platelets at onset, 109/L | ||||
| ≥ 100 | 1.0 | 1.0 | ||
| < 100 | 1.43 (0.6-3.6) | .42 | 1.50 (0.8-2.9) | .24 |
| Time since onset | ||||
| Per month | 1.00 (0.98-1.03) | .79 | 1.00 (0.98-1.03) | .66 |
| . | Moderate/severe versus mild (625 vs 100 assessments) . | Severe versus mild/moderate (195 vs 530 assessments) . | ||
|---|---|---|---|---|
| OR (95% CI) . | P . | OR (95% CI) . | P . | |
| Age at transplantation, y | ||||
| Adult < 50 | 1.0 | 1.0 | ||
| Adult ≥ 50 | 0.96 (0.5-1.9) | .91 | 0.96 (0.6-1.6) | .86 |
| Sex | ||||
| Male | 1.0 | 1.0 | ||
| Female | 0.81 (0.4-1.7) | .58 | 0.95 (0.6-1.6) | .85 |
| Donor/patient sex | ||||
| Other | 1.0 | 1.0 | ||
| Female to male | 0.46 (0.2-1.0) | .04 | 0.91 (0.5-1.6) | .75 |
| Donor | ||||
| HLA-matched related | 1.0 | 1.0 | ||
| HLA-matched URD | 0.74 (0.3-1.6) | .43 | 1.10 (0.6-1.9) | .73 |
| HLA-mismatched | 0.66 (0.3-1.6) | .37 | 1.41 (0.6-3.1) | .40 |
| Conditioning | ||||
| Myeloablative | 1.0 | 1.0 | ||
| RIC/NMA | 1.05 (0.5-2.2) | .89 | 1.36 (0.7-2.6) | .36 |
| Stem cell source | ||||
| Peripheral blood | 1.0 | 1.0 | ||
| BM | 0.68 (0.2-2.1) | .55 | 1.38 (0.5-3.8) | .56 |
| Cord blood | 2.70 (0.7-11) | .17 | 0.84 (0.2-4.2) | .83 |
| Patient CMV | ||||
| − | 1.0 | 1.0 | ||
| + | 0.94 (0.5-1.7) | .84 | 0.92 (0.5-1.6) | .76 |
| Donor CMV | ||||
| − | 1.0 | 1.0 | ||
| + | 1.04 (0.6-1.9) | .90 | 1.01 (0.6-1.7) | .98 |
| Diagnosis | ||||
| ALL/AML | 1.0 | 1.0 | ||
| CLL/CML | 0.40 (0.1-1.1) | .13 | 0.78 (0.3-1.9) | .56 |
| MDS | 0.89 (0.4-2.2) | .80 | 0.84 (0.4-1.8) | .65 |
| HD/NHL | 0.36 (0.2-0.8) | .03 | 1.16 (0.5-2.7) | .72 |
| Other | 0.45 (0.2-1.3) | .18 | 0.40 (0.2-1.0) | .05 |
| Disease stage | ||||
| Early | 1.0 | 1.0 | ||
| Intermediate | 1.22 (0.6-2.6) | .60 | 1.12 (0.6-2.1) | .72 |
| Advanced | 1.47 (0.6-3.5) | .38 | 1.23 (0.6-2.4) | .55 |
| KPS at chronic GVHD onset | ||||
| 80+ | 1.0 | 1.0 | ||
| ≤ 70 | 2.71 (1.4-5.1) | .001 | 2.19 (1.4-3.4) | .0007 |
| Missing | 0.95 (0.5-1.9) | .88 | 1.38 (0.8-2.3) | .24 |
| Prior acute GVHD | ||||
| No | 1.0 | 1.0 | ||
| Yes | 1.55 (0.9-2.8) | .15 | 0.89 (0.5-1.5) | .67 |
| Time to onset, mo | ||||
| < 6 | 1.0 | 1.0 | ||
| 6-12 | 0.71 (0.4-1.2) | .23 | 0.81 (0.5-1.4) | .42 |
| ≥ 12 | 1.95 (0.6-6.0) | .20 | 1.08 (0.5-2.2) | .83 |
| Platelets at onset, 109/L | ||||
| ≥ 100 | 1.0 | 1.0 | ||
| < 100 | 1.43 (0.6-3.6) | .42 | 1.50 (0.8-2.9) | .24 |
| Time since onset | ||||
| Per month | 1.00 (0.98-1.03) | .79 | 1.00 (0.98-1.03) | .66 |
NIH indicates National Institutes of Health; OR, odds ratio; CI, confidence interval; RIC/NMA, reduced-intensity conditioning/nonmyeloablative; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; URD, unrelated donor; and HD, Hodgkin lymphoma.